Smarter data, faster decisions: How biotech funding pressures are reshaping clinical development
As the biotech sector emerges from a challenging funding cycle, its effects continue to shape how companies design trials, generate …
Post
-
-
Loneliness interventions do not have strong sustained effects on memory function
Loneliness, defined as a subjective experience of a discrepancy between the preferred interpersonal relationship an individual has and their actual …
-
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
Biogen’s stock has dropped after it released mixed data on its tau-targeting investigational antisense oligonucleotide (ASO), compounding a previous announcement …
-
FDA clears Atrium’s IND application to begin Corventis trial of ATR 1072
Atrium Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application …
-
Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial
Sound Pharmaceuticals has concluded subject enrolment for its second Phase III clinical trial assessing SPI-1005 in adults with probable or …
-
FDA finalises psychedelic clinical trial guidance
The US Food and Drug Administration (FDA) has finalised its formal guidance for clinical trials involving psychedelic drugs. The FDA document …
-
Arrowhead gains EU authorisation for Redemplo in evolving FCS market
Arrowhead Pharmaceuticals recently announced that the European Commission (EC) has granted marketing authorisation for Redemplo (plozasiran), an innovative apolipoprotein C …
-
AAIC26: Community co-development to guide next generation of diverse trials
Despite progress in bolstering the diversity of clinical trials within the Alzheimer’s disease space, significant barriers to true study diversity …
-
Q32 Bio reports 36-week data from SIGNAL-AA trial’s Part B in alopecia areata
Q32 Bio has reported positive 36-week top line data from Part B of the SIGNAL-AA Phase IIa trial of bempikibart …
-
AI in clinical trial finance
Sitaram Srivatsavai, senior director and head of engineering for product suites, IQVIA, explores how the right AI strategy can unlock …
-
First participant dosed in Ionis’ Phase I-II ASCEND study
Ionis Pharmaceuticals has dosed the first participant in its Phase I-II ASCEND trial evaluating ION337, an investigational ribonucleic acid (RNA)-targeted …
-
Is your quality system built for 2026’s new regulatory reality?
The life sciences industry has always operated under pressure to stay ahead of regulatory change. But 2026 has raised the …
-
Alkermes releases nine-month data as OX2R race heats up
Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has shown continued benefit nine months after the start of treatment in …
-
NewAmsterdam’s cholesterol-lowering therapy shows Alzheimer’s promise
NewAmsterdam’s low-density lipoprotein (LDL) cholesterol-lowering therapy, obicetrapib, has shown promise in diminishing a key biomarker of Alzheimer’s disease – potentially …
-
“Hub-and-spoke” drug manufacturing set to benefit from new FDA rule
The US Food and Drug Administration (FDA) has proposed a new rule that will simplify the registration step for certain …
